Barinthus Biotherapeutics Plc. - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Barinthus Biotherapeutics Plc. is a clinical-stage biopharmaceutical company developing T cell immunotherapies for chronic infectious diseases and autoimmunity. The company is headquartered in the United Kingdom and operates as a single segment focused on research and development. In June 2024, management announced a strategic pivot to prioritize two key candidates: VTP-300 (chronic Hepatitis B) and VTP-1000 (celiac disease), while deprioritizing other programs.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenue | $0 | $334 | $0 | $802 |
| Net Loss | $(16,943) | $(23,824) | $(32,463) | $(42,047) |
| Net Loss Per Share (Basic/Diluted) | $(0.43) | $(0.62) | $(0.83) | $(1.10) |
| Operating Expenses | $18,863 | $26,671 | $35,982 | $48,623 |
| Cash, Cash Equivalents & Restricted Cash | $117,774 (as of June 30, 2024) | |||
| Accumulated Deficit | $(209,010) (as of June 30, 2024) | |||
| Net Cash Used in Operating Activities (YTD) | $(23,828) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to zero for the quarter and year-to-date compared to $0.3 million and $0.8 million in the prior year periods. This is due to AstraZeneca's announcement in May 2024 to withdraw Vaxzevria, eliminating expected royalty receipts.
- Expense Reduction: Total operating expenses decreased by approximately 29% year-over-year for the quarter ($18.9M vs $26.7M). This was driven by a significant reduction in foreign exchange losses (a $4.1M swing from loss to gain) and lower professional and insurance costs.
- R&D Restructuring: Direct R&D expenses decreased due to the completion of the VTP-200 Phase 1b/2 trial and the deprioritization of the VTP-1100 HPV cancer program. However, indirect R&D expenses increased due to severance costs ($0.8M provision) associated with a workforce reduction announced in June 2024.
- Other Operating Income: The company recognized $0.6 million in other operating income for the quarter (nil in prior year) derived from a funding agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) for the VTP-500 MERS vaccine.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects existing cash resources ($117.8 million) to fund operations into the second quarter of 2026. The company anticipates continuing to incur net losses for the foreseeable future.
- Pipeline Focus: Strategic focus is now on VTP-300 (Hepatitis B) and VTP-1000 (Celiac disease). Interim data for VTP-300 showed promising results, with nearly 20% of participants achieving undetectable HBsAg in the HBV003 trial.
- Capital Needs: The company may require additional financing through equity offerings, debt, or collaborations. Failure to secure funding could force delays or termination of development programs.
- Impairment Assessment: Due to the pipeline prioritization and sustained decline in share price, management performed impairment tests on goodwill and intangible assets. No impairment loss was recognized as of June 30, 2024, as assets were deemed recoverable.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional capital, and the impact of global economic conditions and inflation on operating costs.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the projection that cash reserves will last until Q2 2026, considering the burn rate of ~$24M per six months.
- Revenue Cessation: Confirm the impact of the Vaxzevria withdrawal on future royalty streams and the likelihood of any remaining receivables.
- CEPI Funding: Review the terms of the CEPI agreement regarding the $34.8 million potential funding for VTP-500 and the associated royalty obligations.
- Severance Costs: Monitor the actual cash outflow related to the $0.8 million severance provision recorded in Q2.
- Share Issuance: Track the utilization of the "at-the-market" (ATM) sales agreement, which has generated $3.8 million in net proceeds to date.